Letters NATuRE MEDICINE administered matched therapies (no matched treatment), although 9 of them had potential matches for receiving targeted therapies. Instead, they received only 'unmatched' standard-of-care drugs for their respective tumor types, most often due to the treating oncologists' choices (36.4%), patient preference (36.4%), clinical trial availability of other investigational agents (18.2%), and consideration of drug toxicities (9.1%) (Supplementary Table 3 ). The median time from study consent to treatment initiation was less than one month (0.93 months, 95% confidence interval (CI) 0.73-1.4). Since the protocol permitted use of FoundationOne molecular tests performed as part of physicians' routine practice (before enrollment), the median time from molecular results until treatment initiation was two months (95% CI 1.3-2.3).
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. Tumor complexity and heterogeneity suggest that the 'precision medicine' paradigm of cancer therapy requires treatment to be personalized to the individual patient [2] [3] [4] [5] [6] . To date, precision oncology trials have been based on molecular matching with predetermined monotherapies [7] [8] [9] [10] [11] [12] [13] [14] . Several of these trials have been hindered by very low matching rates, often in the 5-10% range 15 , and low response rates. Low matching rates may be due to the use of limited gene panels, restrictive molecular matching algorithms, lack of drug availability, or the deterioration and death of end-stage patients before therapy can be implemented. We hypothesized that personalized treatment with combination therapies would improve outcomes in patients with refractory malignancies. As a first test of this concept, we implemented a cross-institutional prospective study (I-PREDICT, NCT02534675) that used tumor DNA sequencing and timely recommendations for individualized treatment with combination therapies. We found that administration of customized multidrug regimens was feasible, with 49% of consented patients receiving personalized treatment. Targeting of a larger fraction of identified molecular alterations, yielding a higher 'matching score', was correlated with significantly improved disease control rates, as well as longer progression-free and overall survival rates, compared to targeting of fewer somatic alterations. Our findings suggest that the current clinical trial paradigm for precision oncology, which pairs one driver mutation with one drug, may be optimized by treating molecularly complex and heterogeneous cancers with combinations of customized agents.
We conducted Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT), a prospective navigation trial, at two centers (University of California, San Diego Moores Cancer Center and Avera Cancer Institute). Tissue genomic profiling using next-generation sequencing (NGS; Foundation Medicine, 236-405 genes), and, if possible, programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC), tumor mutational burden (TMB), microsatellite instability (MSI) status, and the NGS of blood-derived circulating tumor DNA (ctDNA) were performed. Based on this information, a molecular tumor board (MTB) consisting of oncologists, pharmacologists, cancer biologists, geneticists, surgeons, radiologists, pathologists, and bioinformatics experts focused on selecting customized, multidrug combinations to target a majority of the genomic alterations in each patient's tumor(s) while simultaneously considering potential overlapping drug toxicities. The therapies ultimately administered were based on the treating oncologists' choice, with physicians crafting the regimen by incorporating MTB discussions, as well as patient preference, attention to comorbidities, consideration of drug toxicities, insurance payor coverage of off-label agent(s), and investigational agent clinical trial availability, hence reflecting actual clinical practice in the United States today.
One hundred and forty-nine patients with previously treated, refractory, lethal metastatic cancers (stage IV disease) were consented to the I-PREDICT trial. Eighty-three patients (56%) were treated and considered evaluable for analysis (Supplementary Table  1 and Supplementary Table 2 ). These 83 patients had a median of two prior lines of therapy. The other 66 patients could not be evaluated, mainly because they deteriorated or died before treatment could be initiated (Extended Data Fig. 1 ). The patient demographics of the 83 treated patients are described in Table 1 . The most common primary tumor sites were gastrointestinal (including hepatopancreatobiliary) (42.2%), gynecologic (16.9%), breast (14.5%), and central nervous system (7.2%). The median number of characterized genomic alterations per tumor was 5 (range, 1-20; Table 1 ).
Of the 83 treated patients, 73 (88% of treated patients; 49% of enrolled patients) were administered a personalized, precision therapy consisting of ≥1 molecularly 'matched' treatments (≥1 matched treatment), following receipt of molecular profile results. No two molecular profiles were identical; hence, most treatment regimens were not exactly alike. The other 10 patients (12%) were not Letters NATuRE MEDICINE administered matched therapies (no matched treatment), although 9 of them had potential matches for receiving targeted therapies. Instead, they received only 'unmatched' standard-of-care drugs for their respective tumor types, most often due to the treating oncologists' choices (36.4%), patient preference (36.4%), clinical trial availability of other investigational agents (18.2%), and consideration of drug toxicities (9.1%) (Supplementary Table 3 ). The median time from study consent to treatment initiation was less than one month (0.93 months, 95% confidence interval (CI) 0.73-1.4). Since the protocol permitted use of FoundationOne molecular tests performed as part of physicians' routine practice (before enrollment), the median time from molecular results until treatment initiation was two months (95% CI 1.3-2.3).
The 73 patients (≥1 matched treatment) had previously been treated with a median of 2 (interquartile range (IQR) 1-3) prior lines of therapy. They received a median of two drugs in their onstudy treatment regimens (range, 1-5; Table 1 ). Figure 1a ,b details the percentage of matched genomic alterations in a pathway, complex, or gene that were targeted by the customized therapeutic regimens (median of 2 genomic alterations targeted per patient; range, 1-6). Of the 73 patients, all had matches linked to molecular alterations (see Supplementary Table 2 for molecular results and drug matches with supporting references); in 67 patients (91.8%), the drugs were gene product-targeted drugs, while the others were checkpoint inhibitor immunotherapy, based on the genomic profile (Supplementary Table 4 ). Specifically, a checkpoint inhibitor was administered (alone or in combination with other drugs) to 14 matched patients (19.1%) based on PD-L1 IHC positivity, high/ intermediate TMB, MSI-high status, CD274 (PD-L1) amplification, or when tumors had ≥8 genomic alterations with unknown PD-L1 IHC, TMB, and MSI [16] [17] [18] . Four patients (5.5%) were treated with hormone therapies in combination with other molecularly targeted drugs based on positive hormone status. Only two patients had one genomic alteration and were molecularly matched to one drug. Patients given no matched treatment (N = 10) received a median of 2 drugs (range, 1-3).
As described previously 9, 11 , a 'matching score' system was then utilized for each patient. Blinded to patient outcomes, the investigators calculated the total number of molecular alterations matched to the drugs administered and divided that number by the total number of characterized genomic aberrations. Further details for scoring are delineated in the Methods ('Matching score') [19] [20] [21] [22] [23] [24] . We next stratified patients based on matching scores >50% (designated as high; N = 28 patients) versus ≤50% (designated as low; N = 55 patients including 10 patients with no matched treatment administered (matching scores = 0%); Supplementary Table 1) 19 . The total number of molecular matches for the high group was 67 (mean, 2.4 matches per patient). Patients with high matching scores received a median of 2 drugs in their regimen (range, 1-5 drugs) as did patients with low matching scores (median, 2 drugs (range: 1-4 drugs); Supplementary Table 2 and Supplementary Table 4) .
Patients were followed until progression of disease, treatment intolerability, or death. The overall median follow-up was 10.8 months (95% CI 6.9-14.6; Supplementary Table 5 ). Overall, 30% of patients evaluable for response achieved disease control (defined as stable disease ≥ 6 months (N = 4); complete response (N = 1); or partial response (N = 16)). When patients were stratified to high and low groups, a high matching score was an independent predictor of an increased disease control rate (DCR); 50% of patients with a high matching score achieved disease control compared to 22.4% of patients with a low matching score (P = 0.028; Table 2) . Among the different variables tested, matching score >50% was the only parameter significantly associated with higher DCR (Table 2 and Fig. 1c) . The multivariable analysis confirmed that only a high matching score was an independent predictor of higher DCR (odds ratio (OR), 3.6; 95% CI 1.1-11.8; P = 0.033).
A higher matching score was also an independent predictor of longer progression-free survival (PFS) ( Table 2 and Fig. 1e ) and overall survival (Table 2 and Fig. 1f ) according to the KaplanMeier analysis 20 . All treated patients (N = 83) were included in the PFS and overall survival analyses of high matching score versus low matching score (median PFS, 6.5 versus 3.1 months, P = 0.001; median overall survival, not reached after a median follow-up of 8.5 months versus 10.2 months, P = 0.046). In multivariable Cox regression models, adjusting for patient age, sex, matching score, disease site, combination therapy, and therapy line, a high matching score remained the most significant variable associated with a prolonged PFS (hazard ration (HR) for low versus high matching score, 0.34 (95% CI 0.19-0.62, P = 0.0004)) and with a prolonged overall survival (HR for low versus high matching score, 0.42 (95% CI 0.18-0.95, P = 0.038)).
Generally, PFS becomes shorter with each line of therapy administered. Thus, we compared the PFS in the study (PFS2) with the immediate prior line of unmatched therapy (PFS1), hence, using the patient as their own control. Specifically, we compared the frequency of patients with a PFS ratio (PFS2/PFS1) ≥1.3, based on the work of Von Hoff et al. 7 who reported that 27% (18 of 66) of molecularly matched patients had a PFS ratio of ≥ 1.3. In the current study, a high . P values were computed using a binary logistic regression test. e, Kaplan-Meier curves displaying PFS for patients with a matching score ≤50% (N = 55) versus >50% (N = 28). P values are from the two-sided log-rank test. f, Kaplan-Meier curves displaying overall survival for patients with a matching score ≤50% (N = 55) versus >50% (N = 28). P values were calculated by the two-sided log-rank test. The asterisk represents median overall survival not reached after a median follow-up of 8.5 months.
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NATuRE MEDICINE Survival analyses included 83 patients. DCR analysis (stable disease ≥6 months/partial remission/complete remission (SD ≥6 months/PR/CR)) included the 69 patients evaluable for response; for the remaining 14 patients, the DCR was too early to assess, since these patients had stable disease but had not yet had the 6-month follow-up scan. Only tumor types with at least 9 patients were tested. b P values were computed using binary logistic regression analyses (univariable and multivariable). Variables with P < 0.2 in univariable analysis were included in the multivariable model. c P values were computed using the Kaplan-Meier method (two-sided log-rank test for univariable and Cox regression for multivariate analysis); variables with P < 0.2 in univariable analysis were included in the Cox regression model (multivariable). d The age cutoff chosen corresponds to the median age. e The cutoff of 50% for the matching score was chosen according to the minimum P value criteria 19 . f Gastrointestinal cancer includes hepatopancreatobiliary cancer. g Combination therapy refers to the administration of molecularly matched multidrug regimens. NR, not reached. h The cutoff chosen was the median number of prior lines of therapy administered. P values in bold are those less than 0.05.
NATuRE MEDICINE matching score was the only parameter significantly impacting the PFS ratio ≥1.3 in both the univariable (P = 0.026) and multivariable analyses (P = 0.015; Table 3 and Fig. 1d ). Indeed, 75% of patients reached a PFS ratio ≥1.3 if the matching score was >50% compared to 36.6% if the matching score was ≤50% (P = 0.026; Fig. 1d ). These findings indicate that PFS can be prolonged by 30% or longer in later lines of therapy when a majority of the molecular alterations are targeted.
We also attempted to understand if other parameters were impacting patient outcomes in a sub-analysis that only included patients who received ≥1 matched treatment (N = 73; Supplementary Table 6) . This sub-analysis demonstrated that a time interval between tissue biopsy and molecularly matched treatment initiation of <9 months, as well as the addition of chemotherapy in the regimen, increased the rate of patients achieving disease control (stable disease ≥ 6 months/complete remission/partial remission) in a multivariable analysis (P = 0.031 and P = 0.033, respectively). However, only the matching score remained a favorable independent predictor in the multivariable analysis for the PFS and overall survival analyses (P = 0.004 and P = 0.050, respectively), further validating earlier studies of this methodology 9, 11 . We also evaluated the role of targeting downstream of RAS and TP53, two common mutations in cancers (Fig. 1a,b ). To date, no specific drug is known to directly target RAS. Furthermore, the efficacy of dual specificity mitogen-activated protein kinase kinase 1 (MEK) inhibitors has been circumstantial and mixed 25 . It is unclear if the weak efficacy of current MEK inhibitors for KRAS targeting is a fundamental property of these inhibitors or if it is related to the fact that KRAS alterations are usually accompanied by other drivers that need to be targeted. Of interest in this regard is a recent report demonstrating that a patient with Rosai-Dorfman disease and a single activating KRAS alteration had a remarkable response to the MEK inhibitor cobimetinib 26 . With regard to TP53 aberrations, recent data suggest it may be indirectly/partially targetmatched with vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) inhibitors (perhaps because loss of p53 function is associated with upregulation of VEGF-A) 27, 28 . Thus, we evaluated the DCR, PFS, and overall survival in patients with TP53 and/or RAS mutations who were treated with VEGF/VEGFR and/or MEK inhibitors versus patients with TP53 and/or RAS mutations who were not matched to any therapy (Supplementary Table 7 ). There is no difference between the groups, although the numbers are too small to draw definitive conclusions. However, Wheler et al. 27 addressed this question with regard to TP53 alterations matched to VEGF/VEGFR inhibitors. Their report showed that VEGF/VEGFR inhibitor therapy was independently associated with improvement in all outcome parameters for TP53-mutant patients (but not for TP53 wild-type patients, who received no other molecularly matched agents) treated with VEGF/VEGFR inhibitors (versus those not treated with these agents).
Overall, 16 of 83 treated patients (19.3%) experienced ≥1 serious adverse events (SAE) in the study (14 of 73 (19.2%) with ≥1 matched treatment and 2 of 10 (20%) with no matched treatment administered). The number of drugs in the regimen was unrelated to the number of SAEs. The SAEs deemed at least possibly or probably related to drug therapy tended to be less common in patients with a matching score >50% versus ≤50% (1 (3.6%) versus 7 (15.6%); P = 0.14). There were no treatment-related deaths in this study. Taken together, therapy-related SAEs tended to be more common in the patients who received no matched treatment and in patients with a matching score ≤50%. (Supplementary Tables 8-10) .
Matching single agents (other than immunotherapies for select individuals) to tumors with multiple genomic alterations is unlikely to result in prolonged or complete remission. In fact, only two patients (2.7%) in our cohort with ≥1 matched treatment had only one genomic alteration identified. Yet, precision medicine trials performed to date concentrate on finding commonalities between patients and then matching them to monotherapy, a design consistent with traditional treatment models, but inconsistent with the reality unveiled by genomics. That is, the vast majority of patients with metastatic tumors have numerous genomic alterations that differ from patient to patient [2] [3] [4] [5] [6] . We achieved a matching rate of 49% (73 of 149 patients), a number considerably higher than in many other precision medicine trials of which we are aware. This high matching rate was based on several key factors: (1) molecular interrogation by NGS for a large panel of cancer-related genes, including assessment, when possible, of TMB, MSI status, PD-L1 IHC and ctDNA; (2) timely MTB discussions, which occurred immediately on receipt of molecular results including by ad hoc e-meetings, to inform treatment recommendations without delay; and (3) use of a medication acquisition specialist and clinical trials coordinator to ensure rapid access to drugs. It is important to note that we did not treat canonical tumor types for success. For example, no melanomas were treated and only three lung cancers (3.6%) were included, demonstrating that this approach may be feasible and effective in diseases that are classically not thought of in the setting of molecularly targeted approaches.
The study had several limitations, including the lack of a control group. In addition, the number of alterations detected may depend on the number of genes interrogated in a given panel test. Therefore, the specific matching scores and cutoffs could differ between panels. However, the more comprehensive the panel with regard to cancer-related genes, the more accurate the matching score should be. Further, the important finding herein is that higher degrees of matching are associated with better outcomes than lower degrees of matching, and that higher matching scores often require customized combinations, rather than single agents, as are often given in traditional precision oncology trials. Further validation and assay harmonization studies are needed to determine a universal cutoff for matching, although it remains conceivable that degrees of matching and outcome are related in a continuum. Another limitation relates to the fact that some of the matches, especially in the high matching score group, were to immunotherapy and this was often based on high TMB status. Hence, these results may confound our ability to calculate matching of strictly gene-targeted agents. Nonetheless, our findings demonstrate that genomics and other biomarkers are more broadly useful for matching a variety of drugs beyond genetargeted agents. However, our findings may have a potential selfselection bias for patients that sought out enrollment on the trial or bias based on physician referral. Even so, this study represents realworld practice patterns, and the molecular matching of targets with cognate agents is generally independent of these issues; therefore, it is likely to have low impact on the results. Finally, a limitation of the study is the small number of patients in individual subgroups, such as those with TP53 alterations matched with VEGF/VEGFR inhibitors or RAS mutations matched with MEK inhibitors alone, which precluded determining the efficacy of these matches when not part of a combination regimen. Additional studies with larger sample sizes are needed.
In conclusion, the administration of N-of-1 customized, multidrug combinations targeting multiple identified molecular alterations (discerned by NGS) based on recommendations from a just-in-time MTB was feasible and safe. Characteristics of this intervention (for example, the matching score) were associated with significant improvements in the DCR and all survival parameters. Although we were able to administer ≥1 matched drug to 49% of our patients, substantial numbers of patients still dropped off, mostly due to disease deterioration with hospice placement or demise. Therefore, personalized precision medicine approaches should be instituted earlier in the course of the disease. At present, there is another study group in the I-PREDICT trial investigating the Enrollment is ongoing. Taken together, our findings underscore the safety, feasibility, and importance of designing precision oncology trials that emphasize personalized, individually tailored combination therapies, rather than scripted monotherapies, for patients with lethal cancers. Follow-up studies with greater numbers of patients are needed to confirm our findings. Ethical compliance. During the preparation, submission, conduct, and analysis of this study, we complied with all relevant ethical regulations.
Online content
Informed consent. All patients enrolled on the I-PREDICT study gave informed consent in their native languages via licensed medical interpreters, as well as signed consented forms in their native languages. Patients who were navigated to an investigational drug or drug(s) that were part of an investigational study, signed consent for that study also.
Study design. This was a prospective, open-label, navigation investigation to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with incurable malignancies. This was a non-randomized, histology-agnostic trial. Although there would be a case mix of histologies, we know that individual histologies are composed of a heterogeneous mix of genomic alterations. It is not clear if one case mix is better or worse than another. Thus, we designed the study to test a strategy of molecular matching that may apply across cancers.
Sample size. This feasibility study has descriptive primary analyses to characterize the study findings. There were three groups, and only results from group 3 (previously treated unresectable/metastatic patients) are described herein; groups 1 and 2 (treatment-naive unresectable and treatment-naive metastatic with lethal diseases) are not described and are accruing. An MTB recommended therapy, but treatment decisions were the choice of the physician. The primary study objective was to determine the feasibility of using molecular testing to determine therapy for patients with previously treated cancers with incurable biology (≥50%, 2-year cancer-associated mortality). Primary and secondary end points included: the proportion of patients who receive molecularly targeted matched treatment after recommendations based on genomic analysis (primary end point); and the proportion of patients with actionable genomic alterations and overall response rate, regression rate, PFS and overall survival and incidence of high-grade adverse events (secondary and exploratory end points). Relevant hypotheses included: patients who receive targeted therapy based on recommendations from actionable genomic alteration(s) will yield antitumor activity; the PFS on matched therapy will be greater than on their last unmatched therapy. For evaluation of treatment decisions, the study committee assessed the degree of matching that occurred using the best information available at the time of data evaluation. The original plan was to enroll 75 evaluable patients. Since this was a hypothesis-generating, descriptive trial, this number was later expanded to permit enrollment of up to 1,000 patients. Based on the fact that a minority of patients is usually matched to therapy on precision medicine trials, it was expected that we would show feasibility with 40% of the 75 evaluable patients (N = 30) being matched and 60% treated with no matched therapy (N = 45). With the sample size of 30 matched versus 45 unmatched, we would have 79% power to detect a response rate of 0.25 versus 0.05 in the two arms with a one-sided 10% type I error rate using the continuitycorrected chi-squared test. We calculated that we would have >80% power to detect the difference between the two groups using the log-rank test when the median PFS is 4 months and 2 months for the two arms, respectively. We analyzed group 3 after enrollment of 149 patients; the feasibility to administer matched therapy was confirmed because, of the 83 evaluable treated patients, 73 (88% of evaluable treated patients and 49% of enrolled patients) were matched. The ability to compare matched and unmatched patients was limited by the small number of evaluable unmatched patients (N = 10). As part of the descriptive analysis, we evaluated the effect of the degree of matching in patients with low versus high matching scores (N = 55 versus 28 patients).
Early safety stopping rule. Simon's two-stage design was used. The null hypothesis was that the true response rate is 0.05 and this would be tested against a onesided alternative. In the first stage, 13 patients would be accrued. If there were 0 responses in these 13 patients, the study would be stopped. Other early stopping rules were for >10 drug-related SAEs and >10 drug-related grade 4-5 toxicities.
Early stopping was not triggered in the study.
Data exclusion.
No data were excluded from the analysis.
Replication. Since this is a clinical trial, no replication was possible or performed.
Patients. We analyzed the clinicopathologic and outcome data of 149 patients with previously treated advanced or metastatic solid malignancies who consented to the I-PREDICT study (group 3) during the study period. The study was activated on 13 February 2015. Accrual is ongoing in groups 1 and 2 (patients with treatmentnaive unresectable (group 1) or metastatic (group 2) lethal cancers (defined as ≥50% 2-year mortality)) to meet accrual goals for analysis 29 . Genomic profiling (Foundation Medicine; 236-405 genes) and, if possible, PD-L1 IHC, TMB, MSI status, and NGS of blood-derived ctDNA were performed. An MTB discussed the results immediately on receipt and emphasized customized combination therapies. The attending physician made the final treatment decisions. All analyses were based on the drugs administered.
Sites and investigator communication. The protocol was conducted at two sites: the University of California, San Diego Moores Cancer Center for Personalized Cancer Therapy and the Avera Cancer Institute in Sioux Falls, South Dakota. The study was cross-institutional in that all investigators, regardless of disease affiliation, at each site could enroll patients. Principal investigators and coinvestigators, as well as study coordinators, reviewed the information by teleconference (and/or face-toface meetings for University of California, San Diego investigators/coordinators) at least every two weeks. In addition, retreats at the primary site (University of California, San Diego) to review study information occurred at least every two months, with Avera physicians and staff teleconferenced in as needed.
MTB. MTB face-to-face meetings occurred approximately weekly and were attended by oncologists, surgeons, radiologists, pathologists, basic scientists, geneticists, colleagues from the University of California, San Diego Supercomputer Center, and bioinformatics specialists, as well as a medication acquisition specialist and clinical trial coordinators/navigators 30, 31 . In addition, just-in-time (ad hoc) MTBs occurred electronically for any patients whom the physician felt could not wait for the face-to-face discussion (and for all patients treated at Avera Cancer Institute); in this case, patients were discussed immediately on receipt of results. All MTBs had templated information distribution and complied with HIPAA privacy protections regulations.
NGS, MSI, TMB, and PD-L1 status by IHC. NGS was performed by Foundation
Medicine on tissue and blood (FoundationOne, FoundationOne Heme, and FoundationACT; http://www.foundationmedicine.com; Clinical Laboratory Improvement Amendments (CLIA)-certified). The FoundationOne tissue assay utilized during a majority of the study period interrogates 315 genes, as well as introns of 28 genes involved in rearrangements 32 . The current FoundationOne Heme tissue assay interrogates 406 genes, as well as introns of 31 genes involved in rearrangements, as well as the sequence RNA of 265 genes commonly rearranged in cancer to better identify known and novel gene fusions. Both assays identify all four classes of genomic alterations (that is, base substitutions, insertion and deletions, copy-number alterations, and rearrangements). All specimens were reviewed by a pathologist to ensure specimen viability and tumor content. FoundationACT is a blood-based ctDNA assay for solid tumors that identifies clinically relevant genomic alterations driving the growth of a patient's cancer 33, 34 . It interrogates the 62 most clinically relevant cancer genes in solid tumors and is validated to identify all 4 alteration types (base-pair substitutions, insertions/ deletions, copy-number alterations, and rearrangements). Two patients in this study only had ctDNA results available.
Microsatellite status (a measure of MSI) was determined by assessing the indel characteristics at 114 homopolymer repeat loci in, or near, the targeted gene regions of the FoundationOne assay and was available for N = 52 patients. MSI was reported as MSI-high, MS-stable, MSI-ambiguous, or MSI-unknown when relevant.
The Foundation Medicine Laboratory is CLIA-certified. The FoundationOne CDx (F1CDx) is the first US Food and Drug Administration (FDA)-approved broad companion diagnostic (CDx). The F1CDx TMB result is pending approval in an expanded CDx claim for nivolumab in the front-line setting for non-small cell lung cancer. The TMB categorization (low, intermediate, high) was assigned as described previously 35 . TMB was defined as the number of somatic, coding, base substitution, and indel mutations per megabase (Mb) of genome examined. All base substitutions and indels in the coding region of targeted genes, including synonymous alterations, are initially counted before filtering as described later. Synonymous mutations are counted to reduce sampling noise. While synonymous mutations are not likely to be directly involved in creating immunogenicity, their presence is a signal of mutational processes that will also have resulted in nonsynonymous mutations and neoantigens elsewhere in the genome. Non-coding alterations were not counted. Alterations listed as known somatic alterations in the Catalogue Of Somatic Mutations In Cancer and truncations in tumor suppressor genes were not counted, since the assay genes are biased toward genes with functional mutations in cancer 36 . Alterations predicted to be germline by the somatic-germline-zygosity algorithm were not counted 37 . Alterations that were recurrently predicted to be germline in our cohort of clinical specimens were not counted. Known germline alterations in the Single Nucleotide Polymorphism Database were not counted. Germline alterations occurring with two or more counts in the Exome Aggregation Consortium database were not counted 38 . To calculate the TMB per Mb, the total number of mutations counted is divided by the size of the coding region of the targeted territory. The non-parametric
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While germline genomic alterations in mismatch repair genes (for example, MLH1 and MSH2) and homology-directed repair genes (for example, BRCA1, BRCA2, and ATM), as well as bona fide somatic driver alterations were excluded from the TMB calculations, they were not excluded from use for drug-targeting in patients with ≥1 matched treatment. TMB results were reported as follows: TMB-high corresponds to ≥ 20 mutations per Mb; TMB-intermediate corresponds to 6-19 mutations per Mb; TMB-low corresponds to ≤ 5 mutations/Mb. TMB was reported for all patients in whom a clinical-grade (CLIA), rather than a research grade, result was available since only CLIA results can be used for making treatment decisions for patients in the United States.
PD-L1 status (performed by Foundation Medicine) was assessed by IHC using the US FDA-approved Dako 22C3 PD-L1 pharmDx qualitative immunohistochemical assay (pre-diluted by the manufacturer), which localizes PD-L1 expression in both tumor cells and tumor-infiltrating immunocytes within formalin-fixed, paraffin-embedded tissue sections. Detection was performed using the Ventana Optiview DAB Detection System on the Ventana BenchMark ULTRA platform (Roche Diagnostics). If any of these tests had been performed as part of routine physician practice before enrollment, the results could be utilized for recommending therapy.
Hormone receptor antibodies. The hormone receptor antibody analyses were performed as part of standard clinical care at each institution. Estrogen receptor status was assessed by IHC with the Ventana estrogen receptor (SP1) antibody (pre-diluted by the manufacturer) within formalin-fixed, paraffin-embedded tissue sections; detection was performed using the Ventana automated platform at University of California, San Diego. This test was cleared by the FDA and was used according to the manufacturer's instructions. Estrogen receptor status was assessed by IHC using the Dako ID5 estrogen receptor Therapy and matching. Therapy was recommended by the MTB, but the actual therapy given was the choice of the treating oncologist. Treatment was considered 'matched' if at least one agent in the treatment regimen targeted at least one aberration, or pathway component, altered in a patient's molecular profile or a protein preferentially expressed in the tumor (for example, estrogen or androgen receptor or human epidermal growth factor receptor 2 status as assessed by standard-of-care testing other than NGS, or PD-L1 expression assessed by IHC as stated earlier). For small molecule inhibitors, matching was based on a half maximal inhibitory concentration (IC 50 ) of the drug for the target (generally, <100 nM) or for effectors immediately downstream of the gene product altered. Antibodies were considered matched if their primary target was the product of the molecular alteration. Matching designation was confirmed by the senior investigators (R.K. and J.K.S.), who were blinded to patient outcomes at the time of designation. Patients were stratified into those having received at least one matched treatment versus no matched treatment administered, with a subsequent stratification into those who received treatment with matching scores >50% versus ≤50%. For patients navigated to a secondary clinical trial, to which they consented, the doses used were as per the clinical trial for that cohort. Otherwise, dosing combinations of drugs were done according to safety rules gleaned from the literature [21] [22] [23] [24] . If the combination of drugs had established dosing known from clinical trials in the literature, that dosing was utilized. If the dosing was unknown, we used data from our analyses of almost 75,000 patients treated in the literature [21] [22] [23] [24] and further modified this after discussion in our MTB and consultation with our pharmacist (PharmD), as needed. Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided. The safety of the protocol was also monitored by our Data Safety Monitoring Board.
Medication acquisition specialist and clinical trial coordinators. To obtain medications in a timely fashion, a medication acquisition specialist and clinical trial coordinators attended the face-to-face MTBs. They were available immediately on physician request at other times. Their purpose was to assist with obtaining onand/or off-label approved drugs, as well as information about relevant clinical trials utilizing investigational or off-label drugs.
Matching score. An exploratory scoring system (matching score) was developed, as described previously 6, 9 . The matching score was calculated post hoc by investigators blinded to the outcomes at the time and it was based on the actual drugs administered. Under this system, the higher the matching score, the better the match. In general, the matching score was calculated by dividing the number of alterations matched in each patient's tumor (numerator) by the number of characterized aberrations in that patient's tumor (denominator). For instance, if a patient's tumor harbored six genomic aberrations and they received two drugs that targeted three of the patient's genomic alterations, the matching score would be 3 out of 6 or 50%. This is because certain drugs targeted more than one alteration (for example, many small molecule inhibitors often have activity against multiple kinases) and were counted as matches for each identified genomic alteration that was matched.
Other considerations were as follows: two mutations in the same gene that had the same effect (for example, loss of function) counted as one aberration in the denominator; two mutations in the same gene that were known to function differently counted twice; two different structural alterations in the same gene (for example, amplification and mutation) were counted as two aberrations in the denominator since they have different functional effects (for example, overexpression versus activation); two drugs targeting the same alteration were counted twice in both the numerator and denominator if they had wellestablished synergy (for example, the FDA-approved combinations of dabrafenib and trametinib for BRAF mutations, or pertuzumab and trastuzumab for ERBB2 alterations); only if the patient was matched (in part) based on hormone (estrogen receptor) positivity in the tissue biopsied for genomic analysis, the hormone receptor status was then added to both the numerator and the denominator; all variants of unknown significance were excluded; in the case of cell cycle inhibitors that targeted CDK4/6, we counted any concomitant CDK4/6 and CDKN2A/B alterations (N = 2 patients) or CCND1/2/3 and CDKN2A/B alterations (N = 2 patients) as one alteration and one drug target in the numerator and denominator because the CDKN2A protein, p16
INK4a
, directly binds to the CDK4/CDK6/cyclin D1 complex, thus regulating their activity 39, 40 ; TP53 alterations were considered matched to anti-angiogenic agents, based on data showing that TP53 mutations are associated with upregulation of VEGF-A and that treatment of TP53-mutant tumors with anti-angiogenic agents is associated with improved outcomes 27, 28, 41, 42 ; if the patient was treated with immunotherapy (for example, anti-PD-1 or anti-PD-L1 checkpoint inhibitors), the matching score was 100% for PD-L1 IHC high positive, TMB-high, MSI-high results (or MHL1, MSH2, MSH6, PMS2 alterations), or if none of the aforementioned were known, but the patient had ≥ 8 genomic alterations (N = 1 patient) based upon the assumption of a high TMB; if the PD-L1 IHC was low positive, the TMB was intermediate, or there was a CD274 (PD-L1) amplification, the matching score was 50%; if the patient received a combination of a checkpoint inhibitor and a gene-targeted drug that matched one or more of their genomic alterations, the score was >50%. As an example, if a patient had intermediate TMB and an MET amplification, as well as a TP53 mutation, and was treated with nivolumab and the MET inhibitor, crizotinib, the matching score would be >50%; if more than one NGS report was available, the alterations in each report were counted (since there can be heterogeneity between tissue biopsies); if a patient's regimen included drugs that did not match any alteration, those drugs received a matching score of 0. The cutoff of 50% for the analyses of low versus high matching scores was chosen according to the minimum P value criteria Alternative approach to matching score for immune checkpoint blockade. There may be alternative approaches to scoring matches, especially in the case of immunotherapy, since one drug may be used in some circumstances to theoretically target multiple genomic alterations. It is becoming increasingly evident that immune checkpoint blockade and genomics are not separate silos, but rather linked to each other. This is because abnormalities in DNA damage repair and DNA replication can result in increased rates of somatic mutations in tumors. In turn, the presentation of neoantigens generated by the mutanome in combination with immune system activation by checkpoint blockade can distinguish normal from tumor tissue. Based on studies demonstrating a relationship between TMB and immunotherapy response (that is, the higher the TMB, the greater the response rate) and between other gene alterations, such as PD-L1 amplification and response, genomics is directly relevant to selecting patients for immune checkpoint blockade 17, 43 . Furthermore, the FDA has approved the immune checkpoint inhibitor, pembrolizumab, for any solid tumor with alterations in DNA mismatch repair pathway genes (for example, MSH2, MSH6, MLH1, PMS2) due to associated large increases in TMB 35 . Moreover, TMB increases correlate with a higher neoantigen load based on somatic mutation data from the The Cancer Genome Atlas 44 . In turn, these would be expected to be more immunogenic and therefore responsive to immunotherapy 17 . In a retrospective fashion that was unblinded to outcomes, we developed an alternative approach for scoring immune checkpoint blockade matches. In a histology-agnostic fashion, we previously reported objective response rates (%) for patients receiving immunotherapy in the setting of low, intermediate, and high TMB 17 . Therefore, we adopted these objective response rates as the matching scores for intermediate TMB (15 out of 48 = 31%) and high TMB (22 out of 38 = 58%) tumors.
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Four patients (47, 121, 155, A011) had high TMB and received immunotherapy, while four more patients (102, 115, A035, A037) had intermediate TMB and received immunotherapy. Following evaluation with this alternative matching score approach, all eight patients remained in their same assigned group with matching scores >50%. Thus, none of the results changed. Furthermore, if we assessed CD274 amplification targeted with immunotherapy as one alteration targeted by one drug, the two patients (141, A016) with CD274 amplification and 11 or 12 other alterations who received immunotherapy remained in the matching score ≤50% group. Again, the group assignments of the two patients did not change with the alternative scoring. See Supplementary Text for selected examples of immunotherapy and alternative matching score methodology.
Response/outcome end points. All patients were assessed using RECIST v.1.1 by board-certified radiologists at both University of California, San Diego and Avera Cancer Institute. Selected Avera cases were secondarily reviewed at University of California, San Diego. The following radiological end points were considered: (1) DCR = rate of stable disease ≥ 6 months + partial response + complete response according to RECIST v.1.1 (ref. 45 ); (2) PFS of therapy given under the I-PREDICT protocol (PFS2); (3) PFS2 versus PFS1 (immediate prior line of therapy using patients as their own controls) (refs. 7, 46 ); and (4) percentage of patients with a PFS2/PFS1 ratio ≥ 1.3 (ref. 7 ). Stable disease, partial response, or complete response were initially determined per the assessment of the treating physician. Patients with ongoing stable disease for less than six months at the date of data cutoff could not be evaluated for the DCR. However, they were evaluable for PFS and overall survival. PFS was defined as the time from the beginning of therapy to disease progression, or the time to last follow-up for patients that were progression-free. Patients who were progression-free on the date of last follow-up were censored on that date. Overall survival was defined as the time from the beginning of therapy to death, or last follow-up date for patients who were alive (the latter were censored on that date). The cutoff date of the analysis was 15 August 2017 and cutoff date for patients included was consent by the end of June 2017.
Patients could not be evaluated for comparison of PFS on study to prior PFS if prior PFS was for therapy given in the adjuvant or neoadjuvant setting, or if prior therapy included a matched drug. Patients could not be evaluated for therapy outcome if: (1) they did not receive treatment by 6 months after consent; (2) had not received at least 10 d of therapy (if the drug was taken orally); (3) had not received two doses of an intravenous drug given once every two weeks or more often; or (4) had received only one dose of drug in case of an intravenous drug given every three weeks or less frequently.
Data collection and analysis. All data was collected in a Microsoft Access 2013 (v.15.0) database. Logistic regressions were performed for binary end points. HRs for PFS and overall survival were analyzed by the Kaplan-Meier method 20 and the log-rank test was used to compare the survival end points by groups. Cox regression models were used as multivariable analysis when appropriate for survival end points. The importance of a prognostic factor was assessed by the OR, using the log-rank test and logistic regression/Cox regression models. *Treated evaluable patients includes patients who received >10 d of treatment for drugs given on a daily basis (generally drugs given by mouth) or at least two doses of a drug normally given every two weeks or more frequently (the latter generally being intravenous drugs). Only patients whose treatment was reviewed and validated by data analysis lockdown are included. **One patient had inadequate tissue for NGS and declined biopsy; he was later reenrolled after he agreed to undergo biopsy. One treated patient who initially was believed to have prior therapy was found, after data lockdown analysis, to have not received the prior regimen. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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